علاج الخط الأول لسرطان الغدد الليمفاوية لهامش الطحال

References

DOI: 10.1016/j.annonc.2019.10.010

• Rituximab therapy alone (375 mg/m² 4- to 8-weekly doses) can produce a rapid response, with a high overall response rate (>80%) and CRR (>40%) with minimal toxicity.
• Maintenance with rituximab (every 2 months for 1-2 years) may improve PFS, but no OS advantage has been shown to date and maintenance may not be superior to retreatment on demand.
• Rituximab alone is the preferred initial therapy in patients with SMZL [III, A]
• Achievement of CR is defined by normal spleen size, normal blood counts, negative flow cytometry on blood and negative IHC on bone marrow biopsy.